

## Zoster Vaccine (Recombinant) SHINGRIX®

Supplier: GlaxoSmithKline Inc.

**INDICATIONS:** This vaccine is not publicly funded.

### RECOMMENDED BY THE NATIONAL ADVISORY COMMITTEE ON IMMUNIZATION BUT NOT PROVIDED FREE IN BC:

- Should be offered to individuals 50 years of age and older for the prevention of shingles, <sup>A</sup> including those who:
  - have been previously vaccinated with live zoster vaccine (ZOSTAVAX® II) <sup>B</sup>
  - have had a previous episode of shingles <sup>C</sup>

---

### DOSES AND SCHEDULE:

Adults: 2 doses given as 0.5 mL **IM**, 2 to 6 months apart.

---

### ADMINISTRATION:

- Product needs to be reconstituted. Use the diluent provided with the vaccine.
- Administer the entire volume of the reconstituted product.

---

### BOOSTER DOSES:

No booster doses are recommended at this time.

---

### SEROLOGICAL TESTING:

Serological testing is not recommended before or after immunization. <sup>A</sup>

---

### CONTRAINDICATIONS:

1. History of anaphylactic reaction to a previous dose of SHINGRIX®, or to any component of SHINGRIX®.

---

### PRODUCT COMPONENTS:

Potential allergens: polysorbate 80.

Other components: *Quillaja saponaria* Molina fraction 21, 3-O-desacyl-4'-monophosphoryl lipid A, dipotassium phosphate, sodium dihydrogen phosphate dihydrate, sucrose, cholesterol, dioleoyl phosphatidylcholine, disodium phosphate anhydrous, potassium dihydrogen phosphate.

---

<sup>A</sup> SHINGRIX® is indicated for the prevention of shingles in individuals with prior chickenpox infection. Given that nearly all Canadians eligible for this vaccine will have had prior varicella exposure, even if a diagnosis of varicella cannot be recalled, routine serological testing is not recommended. There is no known safety risk associated with vaccination of healthy individuals who are varicella-susceptible.

However, in the rare circumstance that an individual is known to be serologically varicella susceptible, they should be immunized with 2 doses of varicella vaccine rather than zoster vaccine.

<sup>B</sup> There should be an interval of at least 1 year between receipt of live zoster vaccine and administration of SHINGRIX®.

<sup>C</sup> Immunization should be deferred in individuals experiencing an episode of shingles until the acute stage of the illness has fully resolved.

## Zoster Vaccine (Recombinant) SHINGRIX

Supplier: GlaxoSmithKline Inc.

### PRECAUTIONS:

- SHINGRIX® should be used with precaution in those who are pregnant or breastfeeding as there are no data on its use in these populations.
- Individuals with a prior history of Guillain-Barré syndrome should be referred to a primary care provider to discuss the benefits and risk of receiving this vaccine.

---

### SPECIAL CONSIDERATIONS:

- SHINGRIX® may be considered for immunocompromised adults 18 years of age and older.

---

### ADVERSE EVENTS:

**Local:** pain, redness, swelling.

**Systemic:** myalgia, fatigue, headache, shivering, fever, nausea, diarrhea, vomiting, stomach pain.

Very rare cases of Guillain-Barré syndrome have been reported.